ARQL:NSD-ArQule, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 20.00

Change

0.00 (0.00)%

Market Cap

USD 2.42B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ArQule, Inc (ARQL) Stock Analysis:
Based on the ArQule, Inc stock forecasts from 0 analysts, the average analyst target price for ArQule, Inc is not available over the next 12 months. ArQule, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ArQule, Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, ArQule, Inc’s stock price was USD 20.00. ArQule, Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for ArQule, Inc
No recent average analyst rating found for ArQule, Inc

About

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD67.92B 10.04 12.33
REGN Regeneron Pharmaceuticals Inc

N/A

USD66.83B 9.94 8.23
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD57.99B 27.35 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD35.77B 4.66 5.67
BGNE BeiGene Ltd

N/A

USD25.75B N/A N/A
SGEN Seagen Inc

N/A

USD23.32B 55.02 44.86
GMAB Genmab A/S

N/A

USD22.58B 51.93 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
RPRX Royalty Pharma plc

N/A

USD16.81B 20.32 11.89

ETFs Containing ARQL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 1,134.57% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,134.57% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 139.58% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 139.58% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 151.85% N/A N/A N/A N/A
Risk Adjusted Return 91.92% N/A N/A N/A N/A
Market Capitalization 2.42B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 15.78 N/A N/A N/A N/A
Price / Cash Flow Ratio -186.17 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -19.98% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 16.58% N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 2.48 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.